Category: Prescribing Information

There are currently no shortages of GLP1s that we are aware of, therefore there is no longer a restriction on starting new patients on GLP1s if they meet the criteria for 3rd line treatment of Type 2 Diabetes Mellitus. If semaglutide (orally as Rybelsus or via injection as Ozempic), dulaglutide (Trulicity) or tirzepatide (Mounjaro) are

Situation/Background: There is a supply problem with Humulin M3 Vials.  Resupply dates are now anticipated to be mid-June 2024. Initially a temporary switch to Humalog Mix 25 Vial was recommended as an alternative while Humulin M3 Vials were unavailable but now there is a supply problem with Humalog Mix 25 Vials. Resupply dates are currently anticipated to be

The latest medication shortage for diabetes now involves insulin – namely Humalog 10ml vials and Humulin M3. The former is usually prescribed for people on insulin pumps and the latter is most commonly used in older people with Type 2 diabetes (especially in care homes). As you will see from the attached guidance: For Humalog

Following the launch of the guidance for the management of long term high dose steroid therapy – ‘Steroid Safety Bundle’ in June 2023, there has been some amendments. The most recent version of this guidance can be found here – Steroid Safety Bundle: Management of long term high dose steroid therapy . The amendments are

A Medicine Supply Alert Notice (MSAN) has been distributed for Tresiba (insulin degludec) FlexTouch 100units/ml solution for injection 3ml pre-filled pens (MSAN(2023)09.pdf). This is relevant from August 2023 to 2024. Tresiba Penfill® (insulin degludec) 100units/ml solution for injection 3ml cartridges remain available and can support increased demand. Patients will require an alternative insulin pen device for